European Radiology: Measurement of this imaging marker predicts chemotherapy-associated steatohepatitis in breast cancer patients receiving NAC!

According to statistics, breast cancer (BC) is the most common female cancer worldwid.

The ability of many chemotherapeutic agents to cause steatohepatitis has become more apparent and led to the formation of chemotherapy-associated steatohepatitis (CASH.

The incidence of cardiovascular disease (CVD) is significantly increased in BC patients receiving cardiotoxic chemotherapy drugs such as anthracyclines, cyclophosphamide, and trastuzuma.

A study published in European Radiology recently quantified liver fat content by MRI mDIXON-Quant examination to determine the prevalence of CASH, and semi-automated volume analysis software to measure EAT volume on chest CT to explore BC patients after NA.

This study reviewed enrolled patients from October 2018 to April 2020 and divided them into breast cancer non-NAC and NAC group.

A total of 662 breast cancer patients were included (non-NAC group: 445; NAC group: 217.

The present study found that in BC patients receiving NAC, the prevalence of CASH was 48% and the EAT volume was significantly increase.

Original source:

Xiaoxia Wang, Yuchuan Tan, Daihong Liu, et a.